Tranexamic Acid in Primary Total Hip Replacement |
 Randomisation system log-in to secure server here |
A randomised controlled trial of the use of topical application of Tranexamic acid in primary total hip replacement. The objective is to find out whether Tranexamic acid will reduce blood loss and subsequent blood transfusion significantly after total hip replacement when applied topically.
Inclusion Criteria
- All patients undergoing unilateral primary total hip replacement
Patient Exclusions
- Undergoing unilateral primary total hip replacement for tumour.
- Allergic to Tranexamic acid
- Bleeding tendency (e.g. Haemophilic and platelets disorders)
- Warfarin, treatment dose of LMWH or conventional heparin
- History of DVT and pulmonary embolism
- Renal failure with creatinine > 250 micromole/l
- Female subjects of child bearing potential must have a negative pregnancy test
Concomitant treatment
Permitted therapies include:
- Aspirin
- Subcutaneous prophylactic conventional or LMW heparin
|
If you require any help, please contact: Sattar Alshryda |
Randomisation service provided by: Sealed Envelope™.com